Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
39.01
+1.33 (3.53%)
At close: Aug 1, 2025, 4:00 PM
39.76
+0.75 (1.92%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Splunk Revenue
Tonix Pharmaceuticals Holding had revenue of $2.43M in the quarter ending March 31, 2025, a decrease of -2.14%. This brings the company's revenue in the last twelve months to $10.04M, down -2.04% year-over-year. In the year 2024, Tonix Pharmaceuticals Holding had annual revenue of $10.09M with 29.94% growth.
Revenue (ttm)
$10.04M
Revenue Growth
-2.04%
P/S Ratio
8.59
Revenue / Employee
$123,963
Employees
81
Market Cap
288.90M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.09M | 2.33M | 29.94% |
Dec 31, 2023 | 7.77M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 57.37B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TNXP News
- 11 days ago - Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia - GlobeNewsWire
- 22 days ago - Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 - GlobeNewsWire
- 23 days ago - Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine - GlobeNewsWire
- 25 days ago - Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025 - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - GlobeNewsWire
- 6 weeks ago - Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy - Seeking Alpha
- 6 weeks ago - Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 - GlobeNewsWire